[Alpha Tau στο PR Newswire] Η Alpha Tau ανακοινώνει την ολοκλήρωση της εγγραφής της ιαπωνικής κεντρικής κλινικής δοκιμής για υποτροπιάζοντα καρκίνο κεφαλής και τραχήλου

Alpha Tau Medical Ltd. (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has been notified by HekaBio K.K., its clinical trial partner in Japan, that recruitment has been completed in its open-label multi-center pivotal study evaluating the Alpha DaRT in Japanese patients with recurrent Head & Neck cancer after radiotherapy.

Διάβασε περισσότερα εδώ.

Source: https://blog.ourcrowd.com/alpha-tau-announces-completion-of-enrollment-of-japanese-pivotal-clinical-trial-in-recurrent-head-neck-cancer/